Search

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

83.8 1.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

83.73

Max

84.58

Belangrijke statistieken

By Trading Economics

Inkomsten

24M

-167M

Verkoop

40M

195M

EPS

-0.84

Winstmarge

-85.626

Werknemers

834

EBITDA

68M

-113M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+27.81% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.4B

16B

Vorige openingsprijs

82.53

Vorige sluitingsprijs

83.8

Nieuwssentiment

By Acuity

64%

36%

292 / 340 Rangschikking in Healthcare

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 jul 2026, 00:06 UTC

News
Correlated Moves

Alphabet shares are lower after reports of Waymo's potential split from Uber, impacting the robotaxi market dynamics. Barclays maintains a Buy rating on the stock.

25 jul 2026, 00:02 UTC

News
Social Media

Uber Technologies is shifting its autonomous vehicle strategy by dissolving its exclusivity agreement with Waymo in Atlanta and Austin. Shares are higher in after-market trading.

25 jul 2026, 00:02 UTC

News

Boeing Co's $695 billion backlog supports a decade of revenue visibility. Shares are higher in after-market trading, recovering from earlier session volatility.

25 jul 2026, 00:02 UTC

News

ServiceNow shares declined in after-hours trading following a quarterly revenue report of $4 billion and raised subscription income guidance amid AI-related concerns.

25 jul 2026, 00:02 UTC

News

Elme Communities announced the sale of six properties for $294 million. Shares are trading higher in after-market hours following the update on liquidation activities.

25 jul 2026, 00:02 UTC

News
Correlated Moves

Liberty Energy reported Q2 revenue growth to $1.19 billion, but faced margin compression. Shares were roughly flat in after-market trading following the results.

25 jul 2026, 00:01 UTC

News

Under Armour shares are trading lower in after-market hours amid concerns over declining revenue, rising debt, and cash burn of $162.2 million.

25 jul 2026, 00:01 UTC

News

Carrier Global appointed PTC's Neil Barua to its board, effective immediately. Shares are higher in after-market trading amid positive sentiment about the company's strategy.

25 jul 2026, 00:01 UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

25 jul 2026, 00:01 UTC

News

Datadog Inc. is trading higher in after-market hours, buoyed by steady quarter-over-quarter revenue growth despite competition from CoreWeave and broader market turmoil.

24 jul 2026, 23:51 UTC

News

Tenet Healthcare reported second-quarter earnings of $6.12 per share, exceeding estimates. Shares are trading higher in after-market hours following the strong results.

24 jul 2026, 23:46 UTC

News

HF Sinclair Corp has filed a lawsuit against the EPA over biofuel blending delays. Shares rose during after-market hours, maintaining a strong monthly performance.

24 jul 2026, 23:41 UTC

News

Kinsale Capital Group reported Q2 earnings of $5.54 per share, exceeding estimates, with revenue of $548.5 million, driving shares higher in after-market trading.

24 jul 2026, 23:41 UTC

Macro News
ETF Constituents
News

The Vanguard Information Technology ETF is higher in after-market hours, supported by key holdings like Apple and Qualcomm, despite broader market declines.

24 jul 2026, 23:41 UTC

News

Datadog Inc. is higher in after-market trading, benefiting from steady quarter-over-quarter revenue growth despite being surpassed by CoreWeave in total revenue.

24 jul 2026, 23:41 UTC

News

Boeing Co shares advanced in after-market hours, supported by a $695 billion backlog and positive analyst outlook on growth potential.

24 jul 2026, 23:36 UTC

News

KKR & Co Inc shares are lower in after-market hours following a $238.954 million share sale, reflecting potential liquidity concerns and capital allocation shifts.

24 jul 2026, 23:31 UTC

News

Interactive Brokers Group reported a 77% pre-tax profit margin but shares are lower in after-market hours amid concerns over rising interest rates and profitability.

24 jul 2026, 23:21 UTC

News
Social Media

Micron Technology Inc shares are declining in after-market trading amid concerns over potential pricing pressures in the cyclical memory chip market.

24 jul 2026, 23:21 UTC

Social Media
News

Warner Bros Discovery shares are lower in after-market trading as merger plans with Paramount Skydance are postponed until June 2027 amid legal challenges.

24 jul 2026, 23:21 UTC

News

Baker Hughes Co shares rose in after-market hours after a decrease in the active rig count, which fell to 587, the lowest since mid-July.

24 jul 2026, 23:16 UTC

News

CS PowerTech has launched its photovoltaic cell facility in Indiana, boosting Canadian Solar's U.S. manufacturing capabilities. Shares are higher in after-market trading.

24 jul 2026, 23:16 UTC

News

Liberty Energy reported Q2 revenue of $1.19 billion, exceeding estimates. Shares are higher in after-market trading following the earnings release.

24 jul 2026, 23:06 UTC

News

American Airlines Group Inc shares are lower in after-market hours following weaker profit guidance for the third quarter amid rising fuel costs.

24 jul 2026, 23:01 UTC

ETF Constituents
News

Vanguard Growth ETF advances in after-market trading, supported by contributions from Apple, Uber, and Applied Materials, following three lower daily closes.

24 jul 2026, 23:01 UTC

News

Elme Communities announced property sales totaling $294 million and revised liquidating distributions to $16.41 to $16.61 per share, trading higher in after-market hours.

24 jul 2026, 23:01 UTC

News

CACI International Inc. shares declined in after-market trading, influenced by a downturn in the Research & Consulting Services sub-sector.

24 jul 2026, 23:01 UTC

News

Emerson Electric Co shares are lower in after-market trading amid mixed market sentiment influenced by geopolitical tensions and new tariffs from the Trump administration.

24 jul 2026, 23:01 UTC

News

Carrier Global Corp shares declined in after-market hours following the appointment of PTC's Neil Barua to its board, effective immediately.

24 jul 2026, 23:01 UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

27.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 107.39 USD  27.81%

Hoogste 157 USD

Laagste 93 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

18

Buy

1

Hold

0

Sell

Sentiment

By Acuity

292 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat